NTNatalya V. Timkina

Natalya V. Timkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalya V. Timkina has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Local recurrence of an ACTH-producing lung carcinoid: a case of successful reoperation via video-assisted thoracoscopic approach

    by E. I. Zinchenko, D. L. Fateeva, A. S. Petrov, K. A. Solovyova, N. V. Timkina

    Background. According to the International Morphological Classification of Diseases for Oncology, lung carcinoids are classified as malignant epithelial neoplasms. However, carcinoid tumors are rare: less than 6 cases per 100,000 people annually. A typical carcinoid often manifests as a small (less than 3 cm), slowly growing peripheral lung tumor that rarely metastasizes (less than 1 % of cases). However, even with small tumor sizes, approximately 3 % of carcinoids are hormone-producing and can present with paraneoplastic syndromes. The primary treatment for carcinoid tumors is surgery; however, the volume of lung resection, particularly for stage IA peripheral carcinoids, is a subject of intense debate in the current literature. The objective of this study was to present a case of successful reoperation involving a right upper lobectomy using a minimally invasive approach for local recurrence of an ACTH-producing lung carcinoid. The postoperative period was uneventful and clinical manifestations resolved completely. Case description . Patient S., 32, with a confirmed typical carcinoid pT1a cN0M0 with pronounced clinical manifestations of increased ACTH production, experienced a recurrence of symptoms 15 months after an atypical resection of the right upper lobe, along with local tumor recurrence in the form of intrapulmonary lymph node involvement. This situation necessitated a repeat radical surgery involving a thoracoscopic extended right upper lobectomy 2 years after the initial surgery. The postoperative period was uneventful. A follow-up examination after 3 months revealed complete regression of symptoms associated with increased ACTH production. Conclusion. Despite the low prevalence of carcinoid tumors and their low malignancy potential, surgical interventions should adhere to the same oncological principles as for other forms of lung cancer, especially if the tumor is hormonally active. Furthermore, the clinical manifestations of a hormone-producing tumor can allow for early detection of local recurrence or disease progression. When choosing the extent of surgery in patients with carcinoid tumors, it is important to consider not only the tumor size and location but also its hormonal activity. In these cases, radical anatomical lung resection with lymph node dissection is advisable for adequate staging and improved long-term treatment outcomes.

  • Open Access

    Comparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients

    by A. V. Murasheva, T. L. Karonova, O. S. Fuks, N. V. Timkina, A. D. Fedotova, E. N. Grineva, E. V. Shlyakhto

    BACKGROUND: Chronic brain dyscirculation (CBD) is a common type 2 diabetes mellitus (DM) complication that leads to the cognitive dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) can reduce the stroke risk but their effect on CBD is not fully studied.AIM: To study and to compare the effect of SGLT-2i of various selectivity and GLP-1RA on the biochemical and functional parameters of CNS damage in patients with type 2 DM.MATERIALS AND METHODS: Type 2 diabetic patients with target HbA1c level on metformin monotherapy were included in “MET” group (n=43), with non-target HbA1c were divided into groups: “MET+EMPA”, n=47, (empagliflozin therapy), “MET+CANA”, n=41, (canagliflozin therapy), “MET+GLP-1RA”, n=66 (therapy with injectable GLP-1RA). The “Control” group (n=23) consisted of healthy volunteers. In “Control” and “MET” groups at baseline, in the rest groups also after 3 and 6 months neuron-specific enolase (NSE), neurofilament light chains (NLC) levels and cognitive status were determined.RESULTS: NSE was increased in all DM patients. GLP-1RA therapy did not lead to NSE decrease. NSE decreased in “MET+EMPA” group after 3 months and in “MET+CANA” group after 6 months. NLC levels were elevated in patients with non-target HbA1c compared to “Control”. Both SGLT-2i caused a more pronounced decrease in LCN than GLP-1RA after 3 months; after 6 months NLC in all treatment groups did not differ from “Control” group. At baseline all DM patients had impaired cognitive function according to MOCA and MMSE. Empagliflozin treatment resulted in the improvement, but not normalization, of cognitive status by MOCA scale. Canagliflozin led to cognitive function normalization after 3 months and retention of the effect. GLP-1RA use was associated with mental function normalization after 6 months. Satisfactory glycemic control was achieved in all groups.CONCLUSION: Type 2 DM is characterized by CNS damage even with satisfactory glycemic control. GLP-1RA and SGLT-2i have a protective effect in CBD in DM; the protective potential of low-selective canagliflozin is probably more pronounced, as it manifests in biochemical and functional parameters improvement. The neurotropic effect of GLP-1RA and SGLT-2i is not due solely to their effect on the glycemic profile.


  • Open Access

    Fibroblast growth factor 21: a novel link in the development and treatment of metabolic disorders

    by A. A. Mikhailova, M. V. Sharypova, A. V. Simanenkova, Yu. V. Cheburkin, O. S. Fuks, N. V. Timkina, V. A. Dyachuk, T. L. Karonova

    In recent years, fibroblast growth factor 21 (FGF21) has garnered increasing attention as a metabolic regulator. It plays a role in the development of tissue insulin sensitivity, exerts beneficial effects on carbohydrate and lipid metabolism, and exhibits antihyperglycemic and antilipidemic properties. Elevated FGF21 levels have been observed in patients with type 2 diabetes, obesity, non-alcoholic fatty liver disease, and a range of other conditions. This may indicate either resistance to FGF21 or a compensatory response to metabolic stress. Evidence suggests that FGF21 can be considered both a marker of several metabolic disorders and a potential therapeutic agent for the treatment of significant societal health issues. Objective. The objective of this review is to summarize the data published to date in the literature, including meta-analyses, reviews, and original studies, focusing on the diagnostic and potential therapeutic role of FGF21 in metabolic disorders.


  • Open Access

    SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke

    by Anna Murasheva, Oksana Fuks, Natalya Timkina, Arina Mikhailova, Timur Vlasov, Konstantin Samochernykh, Tatiana Karonova

    Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- and cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, and mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity and GLP-1RA on brain damage volume and neurological status in non-diabetic and diabetic rats and to investigate the underlying mechanisms. Methods: Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug. Control animals were administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume. We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups. After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement. Results: In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin. DULA improved neurological status compared with MET and SGLT-2i treatment. All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB. In DM, similarly, all the drugs had infarct-limiting effects. Neurological deficit was most pronounced in the untreated diabetic rats and was reduced by all study drugs. All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB. None of the drugs affected neuron-specific enolase. Conclusions: SGLT-2i and GLP-1RA are neuroprotective in experimental stroke. GLP-1RA might be more effective than SGLT-2i as in non-diabetic conditions it influences both brain damage volume and neurological status. All study drugs decrease neuronal damage, while GLP-1RA and highly selective SGLT-2i EMPA, but not low-selective CANA, also have an impact on neuroglia in diabetic conditions.


  • Open Access

    Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke

    by T. L. Karonova, A. V. Murasheva, N. V. Timkina, O. S. Fuks, E. V. Shlyakhto

    Introduction. Stroke remains one of the major causes of death in type diabetes mellitus (DM). Injectable form of glucagon-like peptide-1 receptor agonist semaglutide, Ozempic® decreases the stroke risk. In Russia there appeared a biosimilar Semavic® but its effects on the brain are not yet studied.Aim. To compare neuroprotective properties of Semavic® and Ozempic® while used before ischemic stroke in rats without DM.Materials and methods. The study was conducted in male Wistar rats that were divided into the following groups: “Control” (n = 10) – 0.9% NaCl, “MET” (n = 9) – metformin 200 mg/kg once daily per os, “Ozempic” (n = 10) – Ozempic® 0.012 mg/kg s.c. once daily, “Semavic” (n = 9) – Semavic® 0.012 mg/kg s.c. once daily. After 7 days ischemic stroke was modelled, after 48 hour of reperfusion neurological deficit and brain damage volume were evaluated. Glycemia was measured on the 3rd, 7th days as well as during and after ischemia.Results. None of the study drugs caused hypoglycemia including in poststroke period. Neurological deficit in “MET” group did not differ from that in the “Control” (11.00 [6.50; 12.50] and 10.0 [6.25; 12.00] scores). Both semaglutide drugs caused comparable improvement in neurological status (14.00 [12.00; 18.00] and 14.00 [11.00; 18.00] scores in “Ozempic” and “Semavic” groups). Brain necrosis volume in “Control” group was 16.60 [13.40; 28.58] %. All the study drugs had infarct-limiting effect but brain damage volume in “Ozempic” (6.00 [4.32; 8.44] %) and “Semavic” (7.69 [2.99; 11.33] %) was smaller than in “MET” group (13.07 [8.67; 29.94] %). There were no differences between semaglutide drugs.Conclusions. Biosimilar Semavic® and original Ozempic® demonstrate comparable neuroprotective effect while used in animals without DM prior to ischemic stroke modelling. This protective effect is not due to the drugs’ influence on glycemic profile.


  • Open Access

    Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation

    by A. V. Simanenkova, O. S. Fuks, N. V. Timkina, D. A. Sufieva, O. V. Kirik, D. E. Korzhevskii, T. D. Vlasov, T. L. Karonova

    BACKGROUND: Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients’ disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.AIM: To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.MATERIALS AND METHODS: The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the “MET” group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the “MET+EMPA” group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.RESULTS: Both in the “MET+EMPA” and the “MET” groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the “MET” group, 3.22 (2.94; 3.54) ng/ml in the “MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.CONCLUSION: Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifested in an improvement in cognitive status and a decrease in NLC level. Empagliflozin reduces neuronal damage and abnormal microglial activation.


  • Open Access

    Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i

    by Anna Simanenkova, Oksana Fuks, Natalya Timkina, Alina Islamova, Dina Sufieva, Оlga Kirik, Dmitrii Korzhevskii, Timur Vlasov, Tatiana Karonova

    Background: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke. Methods: DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage. Results: Brain damage was similar in “DM” and “Control” (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with “DM” and “Control” whereas the necrosis volume in “DM+Liraglutide” was smaller than in “DM+Canagliflozin” and did not significantly differ from “DM+Dulaglutide” (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in “DM” than in “Control”, while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between “DM” and “Control”. Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in “DM” and “Control”. Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter. Conclusions: GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.


  • Open Access

    Bone remodeling parameters in patients with type 1 diabetes mellitus and diabetic peripheral polyneuropathy of varying severity

    by N. V. Timkina, A. V. Murasheva, A. O. Ustyuzhanina, F. M. Radugin, A. T. Chernikova, E. Yu. Vasilieva, T. L. Karonova

    BACKGROUND: Diabetic peripheral polyneuropathy (DPPN) is a common and early chronic complication of diabetes mellitus (DM). This complication can be associated with bone tissue damage and low-trauma fractures, particularly in type 1 DM. Therefore, evaluating the relationship between DPPN and bone metabolism parameters is crucial for clinical practice.AIM: To assess bone remodeling parameters in patients with type 1 DM with varying degrees of DPPN.MATERIALS AND METHODS: The study included 90 patients with type 1 DM and DPPN aged 18 to 55 years on stable insulin therapy for the past 3 months. Assessment was conducted for levels of HbA1c, 25(OH)D, total calcium (Ca), phosphorus (P), parathyroid hormone (PTH), osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), fibroblast growth factor 23 (FGF-23) in serum. The degree of neurological deficit was determined using the Neuropathy Disability Score (NDS), Neuropathy Symptoms Score (NSS), and Michigan Neuropathy Screening Instrument (MNSI). Dual-energy X-ray absorptiometry (DXA) was performed to determine bone mineral density (BMD) and trabecular bone score (TBS).RESULTS: Regardless of the degree of DPPN severity, patients with type 1 DM were comparable in HbA1c and 25(OH)D levels. A direct correlation was found between the severity of neurological disorders and BMI (r=0.214; p=0.044) and duration of DM (r=0.246, p=0.019). Vitamin D insufficiency and deficiency were diagnosed in 79% of examined patients with type 1 DM, but the level of 25(OH)D in serum did not depend on the degree of DPPN severity, HbA1c level, duration of DM, and daily insulin dose (p>0.05). A positive correlation was established between PTH level and severity of neurological symptoms, and a ­negative one with HbA1c level. Patients with type 1 DM and varying degrees of DPPN did not differ in BMD and TBS. A Z-score of less than -2.0 SD was only recorded in six patients, and partially degraded microarchitecture of bone tissue was observed in 8 patients.CONCLUSION: Therefore, BMD, TBS, and bone remodeling markers in patients with type 1 DM and DPPN were independent of the degree of neurological deficit, degree of compensation, and duration of DM. Vitamin D deficiency is common in most patients with type 1 DM, but the 25(OH)D level is not influenced by HbA1c level, duration of the disease, and daily insulin dose.

  • Open Access

    Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model

    by A. V. Simanenkova, O. S. Fuks, N. V. Timkina, P. A. Tikhomirova, T. D. Vlasov, T. L. Karonova

    Background.Ischemic stroke is one of the leading causes of death in patients with type 2 diabetes mellitus (DM). According to the results of clinical and experimental studies, the ability of glucagon-like peptide-1 receptor agonists (GLP-1RA) to reduce the risk and severity of stroke in DM has been proven; data on the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) effect are scarce. There has been no direct comparative study of the GLP-1RA and SGLT-2i neuroprotective effect.Objective.To evaluate and to compare the effect of GLP-1RA of varying duration of action and SGLT-2i of varying selectivity on the neurological deficit severity and the brain damage volume in a transient focal brain ischemia model in rats without DM.Design and methods.Male Wistar rats were divided into groups (n = 10 each) depending on the therapy received: “EMPA” (empagliflozin per os 2 mg/kg once daily), “CANA” (canagliflozin per os 25 mg/kg once daily), “LIRA” (liraglutide 1 mg/kg s. c. once daily), “DULA” (dulaglutide 0,12 mg/kg s. c. every 72 hours), “SEMA” (semaglutide 0,012 mg /kg s. c. once daily), “MET” (metformin per os 200 mg/kg once daily — comparison group), “Control” (administration of 0,9 % NaCl solution s. c. once daily). After 7 days, all groups underwent transient focal 30-minute filament middle cerebral artery occlusion. After 48 hours of reperfusion, neurological deficit was assessed using the Garcia scale, then the brain was collected and sections were stained with 1 % triphenyltetrazolium chloride solution to calculate the damage volume.Results.Neurological deficit severity in the “LIRA” (14,50 (12,25; 15,25) points) and “SEMA” (14,00 (13,50; 18,00) points) groups was significantly less than in the “Control” group (11.00 (6,75; 12,00) points). The use of both SGLT-2i, as well as metformin, had no effect on the neurological status. At the same time, therapy with all study drugs had an infarct-limiting effect, compared with the “Control” group (damage volume 24,50 (14,69; 30,12) % of the total brain volume). At the same time, the brain damage volume in the “MET” group (12,93 (6,65, 26,66) %) was greater than that in the “EMPA” (6,08 (2,97, 7,63) %), “CANA” (5,11 (3,96; 8,34) %), “LIRA” (3,40 (2,09; 8,08) %), “DULA” (4,37 (2,72; 5,40) %), “SEMA” (5,19 (4,11; 7,83) %) groups.Conclusions.SGLT-2i of varying selectivity and GLP-1RA of varying duration of action have a similar infarct-limiting effect in acute experimental brain ischemia. At the same time, GLP-1RA neuroprotective potential is higher, as it is characterized by an additional positive effect on the neurological status.


  • Open Access

    Bone remodeling in experimental diabetes mellitus and surgical menopause in Wistar rats

    by N. V. Timkina, A. V. Simanenkova, A. A. Bayramov, M. A. Kokina, N. Yu. Semenova, A. Z. Gagiev, T. L. Karonova, E. N. Grineva

    BACKGROUND: Osteoporosis is metabolic skeletal disease characterized with low bone mass, bone microarchitecture disturbance that together lead to high prevalence of fragility fractures. Postmenopausal osteoporosis accounts for about 80% of the osteoporosis structure in women over 50 years. Diabetes mellitus (DM) is an independent risk factor for low-traumatic fractures. The incidence of both type 2 DM and osteoporosis increases during menopause. Therefore, the study of bone metabolism in experimental diabetes and surgical menopause seems important.THE AIM of the study was to investigate bone metabolism parameters during menopause and experimental type 2 DM.MATERIALS AND METHODS: The half of female Wistar rats had been subjected to bilateral ovariectomy at the beginning of the experiment. Diabetes mellitus (DM) was modelled using a high-fat diet and streptozotocin+nicotinamide. Four weeks after the following groups were formed: «Сontrol» (females without any interventions receiving standard chew, n=5) «OE» (females after ovariectomy n=5), «DM» (females with DM, n=4), «OE+DM» (females after ovariectomy with DM, n=4). The observation period lasted 8 weeks. Bone turnover and calcium-phosphorus metabolism markers (osteocalcin, osteoprotegerin (OPG), nuclear factor-kappa-beta receptor activator ligand (RANKL), sclerostin, fibroblast growth factor-23 (FGF-23), calcium, phosphorus) were measured in the end of experiment. Bone histomorphometry was performed after euthanasia.RESULTS: Phosphorus level was significantly lower both in the «OE» group (1.63 [1.58; 1.65] mmol/L) and in the «DM» group (2.81 [2.57; 2.83] mmol /l) compared to the «Control» group (3.12 [2.55; 3.24] mmol/l) (pCONCLUSION: DM induction can significantly inhibit bone remodeling in animals without menopause, which is reflected in a lower osteocalcin level. Bone turnover during DM and surgical menopause is characterized by lower RANKL levels and higher OPG/RANKL ratio. The effect of ovariectomy on bone metabolism was manifested in more extensive decrease in bone trabeculae area than in DM.